Table 2.
Median ages (Inter Quartile Range-IQR) of patients diagnosed with myeloid malignancies: HMRN 2004 to Aug 2013.
| All patients |
Males |
Females |
||||
|---|---|---|---|---|---|---|
| Total N = 5231 | Myeloid de novo N = 4945 | Total N = 2879 | Myeloid de novo N = 2691 | Total N = 2378 | Myeloid de novo N = 2254 | |
| All myeloid malignancies | 72.4 (61.6–80.2) | 72.5 (61.3–80.4) | 72.0 (61.8–79.6) | 72.1 (61.5–79.8) | 72.7 (61.2–81.1) | 72.9 (60.9–81.4) |
| Acute myeloid leukaemia(AML) | 70.6 (57.3–79.1) | 70.9 (55.4–79.6) | 69.8 (57.4–78.2) | 69.8(55.3–78.4) | 71.2 (57.2–80.4) | 71.7 (56.5–81.0) |
| AML, not otherwise specified | 73.7 (62.4–81.5) | 73.7 (62.3–81.7) | 72.4 (61.7–79.9) | 72.4(61.5–80.0) | 75.8 (64.3–84.0) | 75.8 (64.0–84.0) |
| AML with myelodysplasia-related changes | 70.0 (63.4–75.5) | 77.0 (72.2–78.2) | 70.1 (63.6–75.3) | 75.1(72.2–78.0) | 69.9 (62.4–76.8) | 77.6 (73.5–78.6) |
| AML with NPM1 mutation | 72.0 (57.3–79.0) | 72.0 (57.6–79.0) | 70.6 (50.3–79.5) | 70.6(50.3–79.5) | 72.3 (60.0–78.9) | 72.3 (60.0–78.9) |
| Acute promyelocytic leukaemia(APL) | 47.2 (33.1–63.1) | 47.2 (33.1–63.1) | 48.0 (33.1–63.1) | 48.0(33.1–63.1) | 47.1 (32.8–60.9) | 47.1 (32.8–60.9) |
| AML, core binding factor | 42.9 (27.6–56.9) | 41.8(28.4–57.2) | 44.3(24.6–54.6) | |||
| AML, probable therapy related | 71.9 (59.7–77.4) | 72.4 (59.5–78.4) | 72.6 (67.7–76.6) | 72.7(66.8–77.4) | 68.6 (58.6–78.4) | 67.5(58.6–78.5) |
| AML with MLL(11q23) | 20.3 (13.9–43.8) | 29.2(13.9–44.6) | 20.3(13.2–39.4) | |||
| Myelodysplastic syndromes(MDS) | 75.7 (68.5–81.7) | 75.7(68.5–81.7) | 75.7(68.5–81.4) | 75.8(68.6–81.4) | 75.6(68.5–82.6) | 75.7(68.5–82.6) |
| Refractory cytopenia with multilineage dysplasia (RCMD) | 75.7 (69.3–81.5) | 75.7(69.3–81.5) | 75.7(69.4–81.2) | 75.7(69.6–81.2) | 75.9(68.5–82.5) | |
| Refractory anaemia with excess blasts (RAEB) | 74.5 (66.7–81.3) | 74.6(66.8–81.5) | 74.9(67.2–81.0) | 75.0(67.4–81.0) | 73.6(65.9–81.9) | 74.2(65.9–81.9) |
| Refractory anaemia with ring sideroblasts (RARS) | 77.6 (71.4–83.5) | 77.5(71.4–83.5) | 76.9(69.6–83.0) | 76.9(69.6–82.3) | 78.9(72.1–83.7) | 78.9(72.1–83.7) |
| Myelodysplastic syndrome (5q-) | 72.0(61.7–78.0) | 78.6(70.2–84.0) | 69.6(61.4–77.3) | |||
| Myeloproliferative neoplasms (MPN) | 70.3(58.5–79.2) | 70.2(58.4–79.2) | 68.2(57.6–77.8) | 68.1(57.6–77.8) | 71.7(59.9–80.4) | 71.7(59.7–80.3) |
| Chronic MPNsa | 71.4(60.7–79.9) | 71.4(60.6–79.9) | 69.7(60.0–78.8) | 69.6(59.8–78.8) | 72.5(61.7–81.1) | 72.5(61.7–81.1) |
| Chronic myeloid leukaemia (CML) | 59.1(46.8–71.1) | 59.1(46.8–71.1) | 57.7(46.7–69.5) | 57.8(46.7–69.5) | 61.3(47.7–73.1) | 61.2(47.3–73.0) |
| Myelofibrosis | 73.7(65.7–79.8) | 74.1(65.3–80.0) | 72.0(63.4–79.0) | 72.8(63.4–79.1) | 75.4(68.4–81.9) | 75.6(68.4–81.9) |
| Systemic mastocytosis | 59.3(37.6–69.2) | 70.6(66.2–72.2) | 48.3(34.6–59.9) | |||
| MDS/MPN | 77.2(69.4–82.8) | 77.4(70.7–83.1) | 76.3(69.4–82.0) | 76.4(69.4–82.4) | 77.8(70.0–83.5) | 78.4(71.6–84.2) |
| Chronic myelomonocytic leukaemia | 77.4(71.5–82.9) | 77.4(71.6–83.1) | 76.4(69.9–82.0) | 76.4(71.3–82.1) | 78.4(72.5–83.5) | 78.9(73.4–84.2) |
| MDS/MPN, unclassifiable | 77.5(67.6–82.9) | 78.4(71.3–84.1) | 77.2(67.6–82.4) | 78.4(71.7–82.9) | 77.7(68.0–85.0) | 78.4(71.0–86.4) |
| Atypical chronic myeloid leukaemia | 71.4(66.7–81.8) | 72.0(66.7–81.8) | 71.4(68.2–81.8) | 73.2(67.8–82.5) | 68.1(55.3–79.8) | |
a
Polycythaemia vera, essential thrombocythaemia, MPNs unclassified.